Unravelling the Role of Obesity and Lipids During Tumor Progression

Overview

Journal Front Pharmacol

Date 2023 Apr 17

PMID 37063269

Authors

Junzhe Zhao

Keene Lee

Han Chong Toh

Kong Peng Lam

Shi Yong Neo

Affiliations

Soon will be listed here.

Abstract

The dysregulation of the biochemical pathways in cancer promotes oncogenic transformations and metastatic potential. Recent studies have shed light on how obesity and altered lipid metabolism could be the driving force for tumor progression. Here, in this review, we focus on liver cancer and discuss how obesity and lipid-driven metabolic reprogramming affect tumor, immune, and stroma cells in the tumor microenvironment and, in turn, how alterations in these cells synergize to influence and contribute to tumor growth and dissemination. With increasing evidence on how obesity exacerbates inflammation and immune tolerance, we also touch upon the impact of obesity and altered lipid metabolism on tumor immune escape.

Citing Articles

High-Resolution Magic Angle Spinning Nuclear Magnetic Resonance Spectroscopy of Paired Clinical Liver Tissue Samples from Hepatocellular Cancer and Surrounding Region.

Fernandes W, Harris N, Zamalloa A, Adofina L, Srinivasan P, Menon K Int J Mol Sci. 2024; 25(16).

PMID: 39201610 PMC: 11354908. DOI: 10.3390/ijms25168924.

Exosomal circRNA: emerging insights into cancer progression and clinical application potential.

Zhang F, Jiang J, Qian H, Yan Y, Xu W J Hematol Oncol. 2023; 16(1):67.

PMID: 37365670 PMC: 10294326. DOI: 10.1186/s13045-023-01452-2.

References

Wang Y, Viscarra J, Kim S, Sul H . Transcriptional regulation of hepatic lipogenesis. Nat Rev Mol Cell Biol. 2015; 16(11):678-89. PMC: 4884795. DOI: 10.1038/nrm4074. View

Wang D, DuBois R . The Role of Prostaglandin E(2) in Tumor-Associated Immunosuppression. Trends Mol Med. 2015; 22(1):1-3. PMC: 4762482. DOI: 10.1016/j.molmed.2015.11.003. View

Fhu C, Ali A . Fatty Acid Synthase: An Emerging Target in Cancer. Molecules. 2020; 25(17). PMC: 7504791. DOI: 10.3390/molecules25173935. View

Sukhorukov V, Khotina V, Chegodaev Y, Ivanova E, Sobenin I, Orekhov A . Lipid Metabolism in Macrophages: Focus on Atherosclerosis. Biomedicines. 2020; 8(8). PMC: 7459513. DOI: 10.3390/biomedicines8080262. View

Krawczyk C, Holowka T, Sun J, Blagih J, Amiel E, DeBerardinis R . Toll-like receptor-induced changes in glycolytic metabolism regulate dendritic cell activation. Blood. 2010; 115(23):4742-9. PMC: 2890190. DOI: 10.1182/blood-2009-10-249540. View

Mohamed E, Sierra R, Trillo-Tinoco J, Cao Y, Innamarato P, Payne K . The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING Signaling. Immunity. 2020; 52(4):668-682.e7. PMC: 7207019. DOI: 10.1016/j.immuni.2020.03.004. View

Flavin R, Peluso S, Nguyen P, Loda M . Fatty acid synthase as a potential therapeutic target in cancer. Future Oncol. 2010; 6(4):551-62. PMC: 3197858. DOI: 10.2217/fon.10.11. View

Lee P, Wu C, Hung Y, Lee C, Chi C, Lee I . Gut microbiota and metabolites associate with outcomes of immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. J Immunother Cancer. 2022; 10(6). PMC: 9226985. DOI: 10.1136/jitc-2022-004779. View

Hu C, Xu B, Wang X, Wan W, Lu J, Kong D . Gut microbiota-derived short-chain fatty acids regulate group 3 innate lymphoid cells in HCC. Hepatology. 2022; 77(1):48-64. PMC: 9970019. DOI: 10.1002/hep.32449. View

10.

Pinyol R, Torrecilla S, Wang H, Montironi C, Pique-Gili M, Torres-Martin M . Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol. 2021; 75(4):865-878. DOI: 10.1016/j.jhep.2021.04.049. View

11.

Ringel A, Drijvers J, Baker G, Catozzi A, Garcia-Canaveras J, Gassaway B . Obesity Shapes Metabolism in the Tumor Microenvironment to Suppress Anti-Tumor Immunity. Cell. 2020; 183(7):1848-1866.e26. PMC: 8064125. DOI: 10.1016/j.cell.2020.11.009. View

12.

Luis G, Godfroid A, Nishiumi S, Cimino J, Blacher S, Maquoi E . Tumor resistance to ferroptosis driven by Stearoyl-CoA Desaturase-1 (SCD1) in cancer cells and Fatty Acid Biding Protein-4 (FABP4) in tumor microenvironment promote tumor recurrence. Redox Biol. 2021; 43:102006. PMC: 8163990. DOI: 10.1016/j.redox.2021.102006. View

13.

Bruun J, Lihn A, Verdich C, Pedersen S, Toubro S, Astrup A . Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab. 2003; 285(3):E527-33. DOI: 10.1152/ajpendo.00110.2003. View

14.

Hatzivassiliou G, Zhao F, Bauer D, Andreadis C, Shaw A, Dhanak D . ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell. 2005; 8(4):311-21. DOI: 10.1016/j.ccr.2005.09.008. View

15.

Arguello G, Balboa E, Arrese M, Zanlungo S . Recent insights on the role of cholesterol in non-alcoholic fatty liver disease. Biochim Biophys Acta. 2015; 1852(9):1765-78. DOI: 10.1016/j.bbadis.2015.05.015. View

16.

Michelet X, Dyck L, Hogan A, Loftus R, Duquette D, Wei K . Metabolic reprogramming of natural killer cells in obesity limits antitumor responses. Nat Immunol. 2018; 19(12):1330-1340. DOI: 10.1038/s41590-018-0251-7. View

17.

Wculek S, Dunphy G, Heras-Murillo I, Mastrangelo A, Sancho D . Metabolism of tissue macrophages in homeostasis and pathology. Cell Mol Immunol. 2021; 19(3):384-408. PMC: 8891297. DOI: 10.1038/s41423-021-00791-9. View

18.

Ma J, Xu H, Wang S . Immunosuppressive Role of Myeloid-Derived Suppressor Cells and Therapeutic Targeting in Lung Cancer. J Immunol Res. 2018; 2018:6319649. PMC: 5889862. DOI: 10.1155/2018/6319649. View

19.

Riazi K, Azhari H, Charette J, Underwood F, King J, Afshar E . The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022; 7(9):851-861. DOI: 10.1016/S2468-1253(22)00165-0. View

20.

Nieman K, Romero I, Van Houten B, Lengyel E . Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochim Biophys Acta. 2013; 1831(10):1533-41. PMC: 3742583. DOI: 10.1016/j.bbalip.2013.02.010. View